Ardea's Phase III Program For Promising Gout Drug Begins To Take Shape
Positive efficacy and clean-as-whistle topline results for unpartnered RDEA594 leave some analysts predicting the drug could become a front-runner in the gout field.
Positive efficacy and clean-as-whistle topline results for unpartnered RDEA594 leave some analysts predicting the drug could become a front-runner in the gout field.